Prestige Consumer Healthcare (NYSE:PBH) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Prestige Consumer Healthcare has been downgraded from a "buy" to a "hold" rating by analysts at Wall Street Zen, reflecting a more cautious outlook on the stock.
• The company's quarterly earnings report showed a miss on earnings per share, with reported earnings of $0.95 compared to a consensus estimate of $1.01, driving further concerns about its financial performance.
• Despite recent changes in institutional holdings, the stock maintains a consensus "hold" rating from analysts and a target price of $93.33.

Wall Street Zen lowered shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a buy rating to a hold rating in a report published on Saturday.

A number of other research firms also recently commented on PBH. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

PBH traded down $1.54 during trading on Friday, hitting $64.04. The stock had a trading volume of 883,975 shares, compared to its average volume of 378,023. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The firm has a market capitalization of $3.16 billion, a P/E ratio of 15.03, a PEG ratio of 1.98 and a beta of 0.43. The company's 50-day moving average price is $79.26 and its 200 day moving average price is $82.09. Prestige Consumer Healthcare has a twelve month low of $63.49 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business's quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.90 earnings per share. On average, equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $84,932,000. Raymond James Financial Inc. acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $42,593,000. Invesco Ltd. boosted its stake in shares of Prestige Consumer Healthcare by 24.7% during the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after purchasing an additional 261,537 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Prestige Consumer Healthcare by 1,073.3% during the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock worth $15,923,000 after purchasing an additional 186,524 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Prestige Consumer Healthcare by 11,580.3% during the 1st quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock worth $13,887,000 after purchasing an additional 160,155 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.